Dr Dan Ford

Dr Ford is a Clinical Oncologist specialising in prostate, bladder and kidney cancers. He is a Specialist Advisor of Uro Oncology at GenesisCare. Together with the Uro Oncology clinical group of consultants he has contributed to the launch of 5-day radiotherapy for prostate cancer, 5# SABR for prostate cancer, re-irradiation for prostate cancer that has returned, and renal SABR. He has previously been Clinical Service Lead for oncology at University Hospital Birmingham, a busy regional referral service, where he led a team of over 25 oncologists.

Dr Ford is actively involved in and deeply committed to cancer research. He is Deputy Clinical Cancer Lead for the West Midlands NIHR Clinical Research Network, whose role is to support and promote research activity across the region.

His work includes being the local lead of the PACE trial looking at profound hypofractionation techniques for localised prostate cancer and helping to advance SABR (stereotactic ablative radiotherapy), which is precision technology used to deliver radiotherapy, originally developed for brain and lung cancer, and is now being applied to other areas such as metastatic prostate cancer.